Post-Approval watch: cancer Drug's safety under scrutiny in india
NCT ID NCT06429761
Summary
This study aims to monitor the safety of an already-approved breast cancer drug, trastuzumab deruxtecan, specifically in Indian patients. It will enroll 100 adults with advanced, HER2-positive breast cancer that has spread and who have already tried other HER2-targeted treatments. The main goal is to track side effects and understand how well the drug is tolerated in this population after its initial approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBangalore, 560017, India
-
Research Site
RECRUITINGDelhi, 110029, India
-
Research Site
RECRUITINGKochi, 682041, India
-
Research Site
RECRUITINGMumbai, 400012, India
-
Research Site
RECRUITINGPune, 411028, India
-
Research Site
RECRUITINGVaranasi, 221005, India
Conditions
Explore the condition pages connected to this study.